Clinical trials located in

Amiens CEDEX 1

Amiens CEDEX 1 city is located in France. Currently, 2 clinical trials are being conducted in this city.

  • CT-EU-00118071

    Evaluating the pharmacokinetics, safety, and tolerability of Filgotinib in children and teenagers with juvenile idiopathic arthritis

    This clinical trial focuses on children and teenagers aged 8 to less than 18 years who have Juvenile Idiopathic Arthritis (JIA). The study aims to evaluate the pharmacokinetics, safety, and tolerability of filgotinib, an oral medication.

    Participants will be divided into three groups based on their body weight and will receive different doses of filgotinib in the form of film-coated tablets taken once daily. The trial will monitor the maximum concentration of the drug in the blood, the area under the concentration-time curve, and any adverse events over a period of up to 96 weeks.

    • Filgotinib
  • A study comparing upadacitinib versus adalimumab in the treatment of rheumatoid arthritis

    This clinical trial is studying a new medication called upadacitinib for treating moderate to severe rheumatoid arthritis. Rheumatoid arthritis is a chronic condition that causes pain, stiffness, swelling, and loss of joint function. The study will compare upadacitinib, which is taken as an oral tablet once daily, to adalimumab (brand name Humira), which is an injection given under the skin every other week.

    The main goal is to see how effective upadacitinib is at reducing disease activity compared to adalimumab. The study will measure the percentage of participants who achieve a certain level of low disease activity based on a score called the DAS28-CRP, which looks at tender and swollen joints, overall disease activity, and inflammation levels.

    This is a double-blind study, meaning neither the participants nor the study doctors will know which treatment each participant is receiving. Participants will attend regular visits at a hospital or clinic for medical assessments, checking for side effects, and completing questionnaires. There may be a higher treatment burden compared to standard care. The study is designed to assess the safety and effectiveness of upadacitinib compared to adalimumab in treating moderate to severe rheumatoid arthritis.

    • Adalimumab
    • Upadacitinib

See more clinical trials in other cities in France: